- Expected topline data for Phase 3 DISSOLVE I & II programs of SEL-212 in chronic refractory gout in Q1 2023 - - To receive $10 million upfront for the execution of a license agreement for Xork, the Company’s next-generation immunoglobulin G (IgG) protease candidate, to be developed with Astellas